The incidence of heart failure with preserved ejection fraction (HFpEF) is increasing and its
challenging diagnosis and management combines clinical, imagistic and biological data …

Described as the 'single largest unmet need in cardiovascular medicine', heart failure with
preserved ejection fraction (HFpEF) remains an untreatable disease currently representing …

Introduction The pathophysiology of heart failure with preserved ejection fraction (HFpEF)
remains incompletely defined. We aimed to characterize HFpEF compared to heart failure …

Tissue inhibitor of metalloproteinases-1 (TIMP-1), an important regulator of matrix
metalloproteinases (MMPs), has recently been shown to interact with CD74, a receptor for …

Heart failure with preserved ejection fraction (HFpEF) is an emerging disease with signs of
nonresolving inflammation, endothelial dysfunction, and multiorgan defects. Moreover …

Matrix metalloproteinase (MMP) activity is tightly regulated by the endogenous tissue
inhibitors (TIMPs), and dysregulated activity contributes to extracellular matrix remodelling …

Sphingolipids are key signaling molecules involved in the regulation of cell physiology.
These species are found in tissues and in circulation. Although they only constitute a small …

OBJECTIVE To assess whether cardiac MRI or various biomarkers can be used to detect
myocardial ischemia and fibrosis in dogs with cardiomegaly secondary to myxomatous …

Improvement of risk scoring is particularly important for patients with preserved left
ventricular ejection fraction (LVEF) who generally lack efficient monitoring of progressing …

Abstract Purpose of Review This review aims to summarize recent developments in
identifying and quantifying both the presence and amount of myocardial fibrosis by imaging …